Q-omics provides the consensus-scored DSCAS profile across patient tissues and cancer cell-line models. DSCAS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DSCAS is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, DSCAS RNA expression shows 11,461 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, STAD, and KIRP as cancer lineages where DSCAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSCAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSCAS survival associations across molecular data types. DSCAS RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSCAS RNA expression–survival associations across cancer types. High DSCAS expression shows unfavorable associations in BLCA, MESO and THCA, but favorable associations in UVM, PAAD and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify UVM as the clearest survival context for DSCAS RNA expression.
This table summarizes DSCAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for DSCAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSCAS shows lower tumor expression in BRCA and higher tumor expression in STAD, KIRC, LUSC, LUAD and READ. The STAD box plot shows higher DSCAS RNA expression in tumor versus normal tissue (log2 FC = +0.267, t-test p < 0.001).
This table shows molecular features associated with DSCAS in patient tissues and cancer cell lines. In patient samples, DSCAS shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
